Electronic Supplementary Material (ESI):

```
Experimental and Theoretical Studies of pH-Responsive Iridium(III) Complexes of Azole and N-Heterocyclic Carbene Ligands
```

Tahmineh Hashemzadeh,¹ Andrew J Christofferson,^{2,3} Keith F. White¹ and Peter J. Barnard^{1*}

Department of Biochemistry and Chemistry, La Trobe Institute for Molecular Science, La Trobe University, Victoria, 3086, Australia, E-mail: p.barnard@latrobe.edu.au

School of Science, STEM College, RMIT University, Melbourne, Victoria 3001, Australia

ARC Centre of Excellence in Exciton Science, School of Science, RMIT University, Melbourne, Victoria 3001, Australia

Table of contents

Synthesis	.S2
High Resolution mass spectra for iridium(III) complexes	S6
Crystallography	.S11
UV-visible pH titration studies for complexes 12-15 and 17-20	.S13
pK_a calculations and computational results	S14
¹ H-NMR and ¹³ C-NMR spectra	.S21
References	.S41



Scheme S1. Preparation of (pyimH) 1, (pybimH) 2 and (phbimH) 3, (pyMebimH) 4, (pyClbimH) 5, 6 and 7.

1. Synthesis

[Ir(ppy)₂Cl]_{2.} This compound was prepared as described previously.¹ To a solution of IrCl₃.xH₂O (1.02 g, 3.42 mmol) in distilled 2-ethoxy ethanol (60 mL) and distilled water (20 mL) was added 2-phenylpyridine (1.2 mL, 8.54 mmol). The mixture was heated at 120 °C under a nitrogen atmosphere. A yellow precipitate appeared after 2 h. The reaction was continued for 16 h and after cooling the resulting yellow crystals were collected and washed with water and ether. (yield 1.49 g, 81%).

¹H NMR (500 MHz, d₆-DMSO): δ = 6.25 (d, J = 7.37 Hz, 1 H), 5.66 (d, J = 7.37 Hz, 1 H), 6.70 (t, J = 7.63 Hz, 1H), 6.76 (t, J = 7.63 Hz, 1H), 6.84 (t, J = 7.63 Hz, 1H), 6.89 (t, J = 7.63 Hz, 1H), 7.45 (t, J = 6.80 Hz, 1H), 7.57 (t, J = 6.80 Hz, 1H), 7.73 (d, J = 7.40 Hz, 1H), 7.78 (d, J = 7.40 Hz, 1H), 8.00 (t, J = 7.77 Hz, 1H), 8.09 (t, J = 7.77 Hz, 1H), 8.18 (d, J = 8.03 Hz, 1H), 8.26 (d, J = 8.03 Hz, 1H), 9.54 (d, J = 5.19 Hz, 1H), 9.80 (d, J = 5.60 Hz, 1H) ppm. ¹³C NMR (500 MHz, d₆-DMSO): δ = 120.0, 120.5, 122.6,

122.9, 123.3, 124.0, 124.3, 125.2, 129.5, 130.0, 130.4, 131.7, 138.8, 139.8, 143.6, 144.1, 145.4, 151.0, 152.3, 152.5, 167.3, 167.7 ppm.

 $[Ir(phbim)_2Cl]_2$. This compound was prepared as described for $[Ir(ppy)_2Cl]_2$ from $IrCl_3.xH_2O$ (0.30 g, 1.00 mmol), (0.4 g, 2.00 mmol) of 2-phenylbenzimidazole 2 in a mixture of 28 mL of 2-ethoxy ethanol and water 3:1 (v/v). The product was obtained as a green solid after the addition of water. (yield 0.48 g, 78%).

¹H NMR (500 MHz, d₆-DMSO): δ = 5.76 (d, J = 7.01 Hz, 1H), 6.35 (d, J = 6.62 Hz, 1H), 6.64 (d, J = 10.2 Hz, 2H), 6.86 (d, J = 8.00 Hz, 2H), 7.32-7.34 (m, 2H), 7.39-7.41 (m, 2H), 7.66-7.71(m, 4H), 8.62 (d, J = 7.65 Hz, 1H), 8.77 (d, J = 7.46 Hz, 1H), 13.67 (s, 1H), 13.87 (s, 1H) ppm. ¹³C NMR (500 MHz, d₆-DMSO): δ = 112.5, 113.0, 117.7, 118.4, 121.8, 122.5, 123.2, 123.4, 123.6, 123.7, 123.8, 124.2, 129.5, 130.3, 131.6, 133.6, 134.0, 134.1, 134.2, 134.7, 140.6, 141.4, 144.7, 152.9, 164.3, 165.1 ppm.

1. This compound was prepared as described previously.² An ice-cold solution of 2pyridinecarboxyaldehyde (20 g, 186.72 mmol) in 25 mL ethanol was added to an ice-cold solution of 40% aqueous glyoxal (27 mL) in 10 mL ethanol, and then ice-cold concentrated aqueous NH₄OH solution (64 mL) was added immediately. This solution was stirred at 0 °C for 1 h, and then warmed to room temperature (RT), and stirred for an additional 5 h. The volatiles were evaporated under reduced pressure and the residue was then extracted six times with diethyl ether (500 mL) which gave 1 as a brown crystalline solid. (yield 13.91 g, 51%).

¹H NMR (500 MHz, d₆-DMSO): δ = 7.08 (s, 1 H, ImH), 7.22 (s, 1 H, ImH), 7.33 (t, 3JHH= 6.19 Hz, 1 H, PyH), 7.86 (t, J = 7.83 Hz, 1 H, PyH), 8.04 (d, J = 7.91 Hz, 1 H, PyH), 8.57 (d, J = 4.81 Hz, 1 H, PyH), 12.78 (s, 1 H, NH) ppm. ¹³C NMR (500 MHz, d₆-DMSO): δ =118.7, 119.4, 122.9, 129.5, 137.2, 145.6, 148.9, 149.0 ppm.

2. This compound was prepared as described previously.^{3, 4} In a 250 mL Schlenk flask under a nitrogen atmosphere a mixture of o-phenylenediamine (1 g, 9.25 mmol), Na₂SO₄ (1.97 g, 13.87 mmol) and benzaldehyde (1.96 g, 18.49 mmol). Compound **2** was obtained as light brown crystals. (yield 1.1 g, 61%).

¹H NMR (500 MHz, d₆-DMSO): δ = 7.19-7.21 (m, 2 H), 7.47-7.60 (m, 5 H), 8.18 (d, J = 7.20 Hz, 2 H), 12.91 (b, 1 H, NH) ppm. ¹³C NMR (500 MHz, d₆-DMSO): δ =122.7, 126.8, 129.4, 130.2, 130.4, 151.7 ppm.

3. This compound was prepared as described for **2** from o-phenylenediamine (1 g, 9.25 mmol), and Na_2SO_4 (1.97 g, 13.87 mmol) in 20 mL dry methanol was prepared. 2-pyridinecarboxaldehyde (1.98 g, 18.49 mmol) in 40 mL of dry methanol was added dropwise and the resulting mixture was stirred at RT, overnight. Then the solution was filtered, and the volatiles were evaporated from the filtrate under reduced pressure yielding a sticky brown solid. This crude compound was suspended in hot acetonitrile and after cooling at RT, the product crystalized and was collected and washed with hexane, yielding **3** as a light brown crystalline solid. (yield 1.3 g, 72%).

¹H NMR (500 MHz, d₆-DMSO): δ = 7.22 (t, J = 6.27 Hz, 2 H, PhH), 7.49-7.68 (m, 3 H), 7.99-8.03 (m, 1 H), 8.32-8.35 (m, 1 H), 8.74-8.76 (m, 1 H), 13.08 (s, 1 H, NH) ppm. ¹³C NMR (500 MHz, d6-DMSO): δ =112.0, 119.3, 121.4, 121.9, 123.0, 124.7, 134.9, 137.5, 144.0, 148.5, 149.4, 150.7 ppm.

4 and **6**. These compounds were prepared as described for **3** from of 4,5-dimethyl-1,2 phenylenediamine (1 g, 7.34 mmol), Na₂SO₄ (1.56 g, 11.01 mmol) and 2-pyridinecarboxaldehyde (1.57 g, 14.68 mmol). The products were purified on silica with hexane and ethyl acetate (9:1 v/v) as the eluent and two compound containing fractions were collected. After removal of the solvent compounds **4** and **6** were obtained as orange solids (yield 0.54 g, 33% and yield 0.31 g, 13% respectively).

¹H NMR (400 MHz, d₆-DMSO): δ= 2.32 (s, 6 H, CH₃), 7.30-7.49 (m, 3 H), 7.96 (t, J = 7.73 Hz, 1 H, PyH), 8.26-8.28 (m, 1 H), 8.69-8.70 (m, 1 H), 12.83 (s, 1 H, NH) ppm. ¹³C NMR (400 MHz, d₆-DMSO): δ =20.04, 111.9, 119.2, 121.1, 124.3, 130.3, 131.9, 133.5, 137.4, 142.6, 148.8, 149.2, 149.9 ppm.

6. ¹H NMR (400 MHz, d₆-DMSO): δ = 2.28 (s, 3 H, CH₃), 2.32 (s, 3 H, CH₃), 6.23 (s, 2 H, CH₂), 6.94 (d, J = 7.87 Hz, 1 H, PyH), 7.17-7.20 (m, 1 H), 7.29 (s, 1 H, PhH), 7.40-7.43 (m, 1 H), 7.52 (s, 1 H, PhH), 7.63 (t, J = 7.44 Hz, 1 H, PyH), 7.94 (t, J = 7.78 Hz, 1 H, PyH), 8.33 (d, J = 8.09 Hz, 1 H, PyH), 8.41 (d, J = 4.26 Hz, 1 H, PyH), 8.57 (d, J = 4.73 Hz, 1 H, PyH) ppm. ¹³C NMR (400 MHz, d6-DMSO): δ =19.9, 20.2, 49.9, 111.0, 119.5, 120.7, 122.3, 123.9, 124.0, 131.1, 132.3, 135.4, 136.9, 137.3, 140.9, 148.5, 148.6, 149.1, 150.2, 157.1 ppm.

5 and **7**. This compound was prepared as described for **3** from 4,5-dichloro-o-phenylenediamine (1.25 g, 7.06 mmol), Na_2SO_4 (1.50 g, 10.60 mmol) and 2-pyridinecarboxaldehyde (1.51 g, 14.12 mmol). Compounds **5** and **7** were obtained as pale-purple solids. (yield 0.64 g, 34% and yield 0.41 g, 16% respectively).

¹H NMR (400 MHz, d₆-DMSO): δ=7.56 (t, J = 6.31 Hz, 1 H, PyH), 7.85 (br. s, 2H, PhH), 8.02 (t, J = 8.05 Hz, 1 H, PyH), 8.31 (d, J = 7.85 Hz, 1 H, PyH), 8.75 (d, J = 4.42 Hz, 1 H, PyH), 13.37 (s, 1 H, NH)

ppm. ¹³C NMR (400 MHz, d₆-DMSO): δ =113.1, 113.3, 120.5, 120.6, 121.8, 125.3, 134.5, 137.7, 143.5, 147.6, 149.6, 153.1 ppm.

7. ¹H NMR (400 MHz, d₆-DMSO): δ =6.28 (s, 2 H, CH₂), 7.18-7.21 (m, 2 H), 7.46-7.49 (m, 1 H), 7.69 (t, J = 7.69 Hz, 1 H, PyH), 7.96-8.00 (m, 3 H), 8.32-8.36 (m, 2 H), 8.62 (d, J = 2.57 Hz, 1 H, PyH) ppm. ¹³C NMR (400 MHz, d₆-DMSO): δ =50.0, 113.1, 120.6, 121.3, 122.5, 124.4, 124.8, 125.1, 125.8, 136.7, 136.9, 137.6, 141.6, 148.8, 149.1, 149.2, 151.8, 156.2 ppm.

8. This compound was prepared as described previously.⁵ A solution of 2-bromopyridine (5.0 g, 31.64 mmol), CuI (0.55 g, 2.88 mmol), L-proline (0.66 g, 5.75 mmol), imidazole (1.96 g, 28.77 mmol) and K_2CO_3 (7.95 g, 57.53 mmol) in 30 mL of DMSO was heated at 60 °C under an atmosphere of nitrogen for 72 h. The cooled mixture was partitioned between water and ethyl acetate (3×50 mL) and the combined organic layers were washed with brine and dried with Na₂SO₄ and the volatiles were evaporated under reduced pressure. The residual oil was purified on silica with hexane and ethyl acetate (9:1 v/v) as the eluent. The product containing fractions were evaporated under reduced pressure and drying the residue in vacuo gave **8** as yellow liquid. (yield 2.62 g, 63%).

¹H NMR (500 MHz, d₆-DMSO): δ = 7.13 (d, 3JHH= 1.17 Hz, 1 H, ImH), 7.33-7.36 (m, 1 H), 7.80 (d, J = 8.24 Hz, 1 H, PyH), 7.94-7.99 (m, 2 H), 8.48 (d, J = 3.32 Hz, 1 H, PyH), 8.54 (d, J = 0.91 Hz, 1 H, ImH) ppm. ¹³C NMR (500 MHz, d₆-DMSO): δ =112.7, 116.5, 122.2, 130.1, 135.0, 140.0, 148.6, 148.8 ppm.

9. This compound was prepared as described for **8**, from 2-bromopyridine (5.3 g, 33.42 mmol), copper iodide (0.58 g, 3.04 mmol), L-proline (0.7 g, 6.08 mmol), 1,2-4 triazole (2.1 g, 30.38 mmol) and potassium carbonate (8.4 g, 60.8 mmol). After removal of the volatiles under reduced pressure the residue was recrystallized from hexane which gave the corresponding coupling product **9** as pure white crystalline solid. (yield 2.93 g, 66%).

¹H NMR (400 MHz, d₆-DMSO): δ = 7.48 (t, J = 5.87 Hz, 1 H, PyH), 7.86-7.88 (m, 1 H, PyH), 8.07 (t, J = 8.21 Hz, 1 H, PyH), 8.30 (s, 1 H, trzH), 8.54 (d, J = 4.85 Hz, 1 H, PyH), 9.37 (s, 1 H, trzH) ppm. ¹³C NMR (400 MHz, d₆-DMSO): δ =113.4, 124.1, 140.6, 142.4, 149.1, 153.5. ppm.

10. To a solution of **8** (0.42 g, 2.91 mmol) in 10 mL acetonitrile was added methyl iodide (0.5 g, 3.52 mmol). The colourless solution was then heated at reflux for 24 h and after cooling, the solvent was evaporated under reduced pressure and the resulting pale-yellow solid was recrystallized from ethanol and washed with ether which gave **10** as a white crystalline solid. (yield 0.61 g, 73%).

¹H NMR (500 MHz, d₆-DMSO): δ = 3.97 (s, 3 H, CH₃), 7.64 (t, J = 6.26 Hz, 1 H, PyH), 7.96 (t, J = 1.81 Hz, 1 H, PyH), 8.00 (d, J = 8.15 Hz, 1 H, ImH), 8.22 (t, J = 8.30 Hz, 1 H, PyH), 8.50 (t, J = 1.79 Hz, 1 H, PyH), 8.65 (d, J = 5.01 Hz, 1 H, ImH), 10.03 (s, 1 H, ImH) ppm. ¹³C NMR (500 MHz, d₆-DMSO): δ = 36.4, 114.1, 119.0, 124.8, 125.2, 135.5, 140.6, 146.4, 149.2 ppm.

11. This compound was prepared as described for **10**, from **9** (0.39 g, 2.65 mmol) and methyl iodide (0.45 g, 3.18 mmol). Compound **11** was obtained as a white crystalline solid. (yield 0.65 g, 85%).

¹H NMR (500 MHz, d₆-DMSO): δ = 3.99 (s, 3 H, CH₃), 7.69 (t, J = 6.18 Hz, 1 H, PyH), 8.02-8.04 (m, 1 H, PyH), 8.22 (t, J = 7.89 Hz, 1 H, PyH), 8.66 (d, J = 4.84 Hz, 1 H, PyH), 9.33 (s, 1 H, trzH), 10.91 (s, 1 H, trzH) ppm. ¹³C NMR (500 MHz, d₆-DMSO): δ =35.0, 114.2, 126.6, 141.5, 142.1, 146.7, 147.4, 149.7 ppm.

2. High Resolution Mass Spectra for iridium(III) complexes

Figure S1. HRMS spectrum of **12** in CH₃OH.

Figure S2. HRMS spectrum of **13** in CH₃OH.

Figure S3. HRMS spectrum of 14 in CH₃OH.

Figure S4. HRMS spectrum of 15 in CH₃OH.

Figure S5. HRMS spectrum of **16** in CH₃OH.

Figure S6. HRMS spectrum of 17 in CH₃OH.

Figure S7. HRMS spectrum of **18** in CH₃OH.

Figure S8. HRMS spectrum of 19 in CH₃OH.

Figure S9. HRMS spectrum of **20** in CH₃OH.

3. X-Ray Crystallography

Compound	13	14	16	17	18
Empirical formula	C ₃₄ H ₃₁ ClIrN ₅ O ₃	C ₃₇ H ₃₆ ClIrN ₅ O _{2.5}	C ₃₂ H ₂₇ ClIrN ₇	C40H36ClIrN6O	C44H41ClIrN6O1.5
Formula weight	785.33	818.36	737.25	844.40	905.48
Temperature/K	159(4)	150(1)	180(4)	150(1)	150(1)
Crystal system	monoclinic	tetragonal	monoclinic	orthorhombic	monoclinic
Space group	$P2_{1}/c$	$P\overline{4}b2$	$P2_{1}/c$	$Pca2_1$	C2/c
a/Å	9.2393(2)	28.0735(4)	8.6419(1)	17.64348(9)	25.9468(6)
b/Å	28.2368(3)		32.2748(5)	8.66040(4)	13.8283(2)
$c/\text{\AA}$	16.1627(4)	8.9606(2)	10.5786(2)	22.95688(13)	24.2672(5)
$\alpha/^{\circ}$					
β/°	132.839(4)		99.392(2)		112.536(3)
γ/°					
Volume/Å ³	3091.9(2)	7062.0(3)	2910.98(8)	3507.80(3)	8042.2(3)
Z	4	8	4	4	8
$\rho_{calc}g/cm^3$	1.687	1.539	1.682	1.599	1.496
μ/mm^{-1}	9.508	3.897	9.996	8.393	7.373
F(000)	1552.0	3256.0	1448.0	1680.0	3624.0
Crystal size/mm ³	0.08 x 0.02 x 0.02	$0.24 \times 0.17 \times 0.08$	0.33 × 0.11 × 0.06	$0.07 \times 0.05 \times 0.03$	$0.21 \times 0.2 \times 0.09$
Padiation	$CuK\alpha$ ($\lambda =$	Mo $K\alpha$ ($\lambda =$	Cu $K\alpha$ ($\lambda =$	$CuK\alpha$ ($\lambda =$	Cu $K\alpha$ ($\lambda =$
Radiation	1.54184)	0.71073)	1.54184)	1.54184)	1.54184)
2Θ range for data	8 00 to 1/2 /8	6 16 to 56 831	8.904 to	7.702 to	7 378 to 136 962
collection/°	0.09 10 142.40	0.40 10 50.854	137.144	139.712	7.578 10 150.902
	$-11 \le h \le 8, -34 \le$	$-36 \le h \le 36, -37$	$-10 \le h \le 10$,	$-20 \le h \le 21, -$	$-31 \le h \le 31, -12$
Index ranges	$k \leq 34, -15 \leq l \leq$	$\leq k \leq 35, -11 \leq l$	$-38 \le k \le 35$,	$10 \le k \le 10, -$	$\leq k \leq 16, -28 \leq l$
	19	≤11	$-12 \le l \le 12$	$27 \le l \le 27$	≤ 29
Reflections collected	30795	91934	53765	68323	40499
	$5812 R_{int} =$	$8552 [R_{int} =$	5339 [$R_{int} =$	$6486 [R_{int} =$	7342 $[R_{int} =$
Independent reflections	0.0338 R =	0.1938 R =	0.0508,	0.0315 R =	0.0382 R =
	0.0196]	0.0813]	$R_{\text{sigma}} = 0.0160$	0.0129]	0.0213]
Data/restraints/parameters	5812/0/382	8552/0/391	5339/0/372	6486/1/445	7342/0/415
Goodness-of-fit on F^2	1.090	1.030	1.183	1.038	1.115
Final R indexes $[I \ge 2\sigma]$	$R_1 = 0.0291$,	$R_1 = 0.0534,$	$R_1 = 0.0340,$	$R_1 = 0.0199$,	$R_1 = 0.0531$,
(/)]	$wR_2 = 0.0686$	$wR_2 = 0.1217$	$wR_2 = 0.0814$	$wR_2 = 0.0514$	$wR_2 = 0.1443$
	$R_1 = 0.0297$,	$R_1 = 0.0715$,	$R_1 = 0.0345$,	$R_1 = 0.0200,$	$R_1 = 0.0548,$
Final R indexes [all data]	$wR_2 = 0.0686$	$wR_2 = 0.1282$	$wR_2 = 0.0818$	$wR_2 = 0.0515$	$wR_2 = 0.1469$
Largest diff. peak/hole/ e	2 41/-1 00	0 97/-0 65	2 30/-1 36	1 31/-0 77	6 88/-2 27
Å-3	2.71/-1.00	0.977-0.03	2.30/-1.30	1.31/-0.//	0.00/-2.2/
Flack parameter		0.045(12)		-0.028(3)	

Table S1. Summary of crystallographic data for complexes 13, 14, 16, 17 and 18.

13, X-ray data was collected on a Rigaku Supernova diffractometer using a CuK α radiation source. The crystal was kept at a steady, T = 159 K, during data collection. A multi-scan absorption correction was applied using CrysAlisPro 1.171.40.53 (Rigaku Oxford Diffraction, 2019). A solution was found in the monoclinic space group $P2_1/c$. All Ir(III)-complex, chloride counter ion and solvent atoms were clearly defined and modelled using anisotropic displacement parameters. All hydrogens were placed at

geometrically estimated positions. Electron density attributed to solvent could not be satisfactorily modelled. A solvent mask was calculated and 12 electrons per unit cell was found, consistent with one water molecule, and removed from the data set.

14, X-ray data was collected on a Rigaku Supernova diffractometer using a Mo*Ka* radiation source. The crystal was kept at a steady, T = 150 K, during data collection. A Gaussian absorption correction was applied using CrysAlisPro 1.171.40.53 (Rigaku Oxford Diffraction, 2019). The X-ray data indicated missing reflections at low angles this is, likely a result of beam-stop interference occurring through the use of Mo radiation and a crystal with a large unit cell. The number of unique reflections used in the analysis was 8552. A systematic analysis of the data for the space group found the best fit to be for the tetragonal space group $P^{\bar{4}}b2$, an R_{int} value of 0.19 is likely a result of the missing reflections. All Ir(III) complex and chloride counter ion atoms were well defined and modelled with anisotropic displacement parameters. Hydrogen atoms were placed at geometrically estimated positions. Solvent molecules could not be satisfactorily modelled. A solvent mask calculated and removed from the data set, $32e^-$ (volume 194 Å³) per asymmetric unit, consistent with 1 MeOH and 1.5 H₂O molecules.

16, X-ray data was collected on a Rigaku Supernova diffractometer using a Cu $K\alpha$ radiation source. A Gaussian absorption correction was applied using CrysAlisPro 1.171.40.53 (Rigaku Oxford Diffraction, 2019). A solution was found in the monoclinic space group $P2_1/c$. All Ir(III)-complex, chloride counter ion and solvent atoms were clearly defined and modelled using anisotropic displacement parameters. All hydrogens were placed at geometrically estimated positions.

17, X-ray data was collected on a Rigaku Supernova diffractometer using a Cu $K\alpha$ radiation source. The crystal was kept at a steady, T = 150 K, during data collection. A multi-scan absorption correction was applied using CrysAlisPro 1.171.40.53 (Rigaku Oxford Diffraction, 2019). A solution was found in the orthorhombic space group *Pca2*₁. All Ir(III)-complex, chloride counter ion and diethyl ether solvent atoms were clearly defined and modelled using anisotropic displacement parameters. All hydrogens were placed at geometrically estimated positions.

18, X-ray data was collected on a Rigaku Supernova diffractometer using a CuK α radiation source. A solution was found in the monoclinic space group C2/c. A multi-scan absorption correction was applied using CrysAlisPro 1.171.40.53 (Rigaku Oxford Diffraction, 2019). The Ir(III) complex and chloride counterion atoms were clearly defined and refined with anisotropic displacement parameters, hydrogen atoms were placed at geometrically estimated positions. Electron density attributed to disordered diethyl ether could not be satisfactorily modelled, a solvent mask was calculated and 66 e⁻ per unit asymmetric,

S12

consistent with 1.5 molecules of diethyl ether, was removed from the data set. Unaccounted for, large peaks of electron density remain in the model. The peaks reside close to the heavy Ir(III) cation. Attempts to perform face absorption corrections resulted in a very low data/parameter ratio and unstable refinement and were not applied in the final HKL file.

4. UV-visible pH Titration Studies for complexes 12-15 and 17-20

Figure S10. UV-vis absorption spectra of (a) 12, (b) 13, (c) 14, (d) 15, (e) 17, (f) 18, (g) 19 and (h) 20 recorded as a function of pH in a mixture of 1:1 BR buffer and DMSO. [Complex] = 50 μ M, [BR buffer] = 20 mM. The pH was adjusted with additions of 2 μ L 6 M NaOH.

5. pK_a Calculations and Computational Results

Figure S11. Molecular structure of complex 13 with atom numbering scheme, which was used as a benchmark to determine the appropriate functional for DFT calculation.

Figure S12. HypSpec 2014 calculated concentration distribution curves for the equilibria species relative to the total complex concentration of 14. The red diamonds indicate the experimental absorbance (350 nm) values, and the red dashed line represents the calculated curve for absorbance at 350 nm relative to solution pH. The solution speciation (concentrations) of the protonated 14 and mono-deprotonated 14_{-H} forms are indicated by the blue and green curves, respectively.

Figure S13. Hypspec2014 calculated concentration distribution curves for the equilibria species relative to the total complex concentration for **19**. The red diamonds indicate the experimental absorbance (350 nm) values, and the red dashed line represents the calculated curve for absorbance at 350 nm relative to solution pH. The solution speciation (concentrations) of the protonated **19**, mono-deprotonated **19**._H and di-deprotonated **19**._{2H} forms are indicated by the blue, black and green curves, respectively.

	Expt.	B3LYP		M062X		mPW1P	W91
item	13	cal.	δ	cal.	δ	cal.	δ
Bond Length, Å							
Ir-N1	2.047	2.07173	1.21	2.06543	0.90	2.05123	0.21
Ir-N2	2.047	2.07318	1.28	2.06347	0.80	2.04976	0.13
Ir-N3	2.175	2.20250	1.26	2.22020	2.08	2.16388	0.51
Ir-N4	2.144	2.17550	1.47	2.17969	1.66	2.13929	0.22
Ir-C1	2.016	2.02993	0.69	1.99760	0.91	2.01413	0.09
Ir-C2	2.020	2.02848	0.42	2.00076	0.95	2.01547	0.22
Total δ			6.33		7.30		1.38

Table S2. Optimised geometry parameters of complex 13 in the ground state: percent error (δ) versus xc functionals with the LANL2DZ basis set and experimental data of 13.

Table S3. Optimised geometry parameters of complex 13 in the ground state: percent error (δ) versus xc functionals with the def2-SVP basis set and experimental data of 13.

	Expt.	B3LYP		M062X		mPW1P	W91
item	13	cal.	δ	cal.	δ	cal.	δ
Bond Length, Å							
Ir-N1	2.047	2.08865	2.03	2.07939	1.58	2.06487	0.87
Ir-N2	2.047	2.08722	1.96	2.07681	1.46	2.06324	0.79
Ir-N3	2.175	2.26592	4.18	2.29659	5.59	2.22275	2.20
Ir-N4	2.144	2.23620	4.30	2.24925	4.91	2.19511	2.38
Ir-C1	2.016	2.02342	0.37	1.98164	1.70	2.00674	0.46
Ir-C2	2.020	2.02392	0.19	1.98471	1.75	2.00725	0.63
Total δ			13.03		16.99		7.33

Figure S14. Calculated Mulliken populations of the frontier molecular orbitals (mPW1PW91/LANL2DZ level of theory) for the mono-deprotonated $(17_{-H} - 20_{-H})$ and di-deprotonated $(17_{-2H} - 20_{-2H})$ forms of complexes 17 - 20.

Figure S15. Contour plots of the HOMO and the LUMO orbitals in addition to the HOMO – LUMO energy band gaps for the protonated forms of complexes 17 - 20. Isovalue = 0.02.

Figure S16. Contour plots of the HOMO and the LUMO orbitals in addition to the HOMO – LUMO energy band gaps for the deprotonated forms of complexes $17_{-H} - 20_{-H}$. Isovalue = 0.02.

Figure S17. Contour plots of the HOMO and the LUMO orbitals in addition to the HOMO – LUMO energy band gaps for the di-deprotonated forms of complexes $17_{-2H} - 20_{-2H}$. Isovalue = 0.02.

Complex	Emission (nm)	Major contributions
12 (protonated)	481	L→H (92%), L→H-1 (2%)
12 (deprotonated)	465	L→H (72%), L+1→H−2 (4%), L+1→H−3 (2%)
13 (protonated)	522	L→H (89%), L→H-1 (6%)
13 (deprotonated)	481	L→H-1 (58%), L→H (23%), L+1→H-1 (5%)
14 (protonated)	513	L→H (77%), L→H−1 (16%)
14 (deprotonated)	488	L→H (43%), L→H-1 (26%), L+1→H (10%), L+1→H-1 (6%)
15 (protonated)	548	L→H (95%)
15 (deprotonated)	473	L→H−1 (66%), L→H (21%)
16 (protonated)	573	L→H (96%)
16 (deprotonated)	443	L+1→H (41%), L→H (18%), L+1→H−2 (2%)
17 (protonated)	526	L→H (89%), L→H−4 (2%)
17 (semi-protonated)	589	L→H (76%), L→H−5 (4%)
17 (deprotonated)	642	L→H (88%)
18 (protonated)	520	L→H (77%), L→H−2 (4%), L→H−4 (2%)
18 (semi-protonated)	589	L→H (88%)
18 (deprotonated)	631	L→H (83%), L→H-2 (6%), L→H-6 (2%)
19 (protonated)	437	L+1→H (52%), L+1→H−1 (7%), L+2→H (7%) L+2→H−1 (4%), L+1→H−2 (3%)
19 (semi-protonated)	457	L→H (84%), L→H−3 (5%)
19 (deprotonated)	478	L→H (74%), L→H-1 (14%), L→H-4 (5%)
20 (protonated)	435	$\begin{array}{c} L+1 \rightarrow H \ (43\%), \ L \rightarrow H \ (14\%), \ L \rightarrow H-1 \ (5\%), \\ L+2 \rightarrow H \ (5\%), \ L+1 \rightarrow H-2 \ (4\%), \ L+3 \rightarrow H \ (4\%), \\ L+2 \rightarrow H-1 \ (3\%), \ L+2 \rightarrow H-2 \ (2\%) \end{array}$
20 (semi-protonated)	471	L→H (86%), L→H-2 (5%), L→H-3 (3%)
20 (deprotonated)	490	L→H (81%), L→H-1 (5%) L→H-4 (4%)

 Table S4. Phosphorescent emissions from TD-DFT calculations.

6. ¹H-NMR and ¹³C-NMR Spectra

Figure S19. ¹³C-NMR spectrum for **1** in DMSO.

Figure S20. ¹H-NMR spectrum for **2** in DMSO.

S	H O M O M
9	41407
-	00000
LO LO	MMNNN
-	
	N//
	130 130 126 126 122

Figure S21. ¹³C-NMR spectrum for **2** in DMSO.

Figure S23. ¹³C-NMR spectrum for **3** in DMSO.

Figure S24. ¹H-NMR spectrum for **4** in DMSO.

Figure S25. ¹³C-NMR spectrum for 4 in DMSO.

Figure S26. ¹H-NMR spectrum for **5** in DMSO.

.55	.47	.74	.34	. 62	. 46
153 149	147	137	134	121	113
				V	/ V

Figure S27. ¹³C-NMR spectrum for **5** in DMSO.

Figure S28. ¹H-NMR spectrum for **6** in DMSO.

Figure S29. ¹³C-NMR spectrum for **6** in DMSO.

Figure S30. ¹H-NMR spectrum for 7 in DMSO.

Figure S31. ¹³C-NMR spectrum for **7** in DMSO.

Figure S32. ¹H-NMR spectrum for **8** in DMSO.

64	33	16	0	22	1	1	
						•	
00 00	39	34	8	53	91	2	
11	H	H	H	H	E	Ξ.	
11						1	
Y						1	

Figure S33. ¹³C-NMR spectrum for **8** in DMSO.

Figure S34. ¹H-NMR spectrum for **9** in DMSO.

9	4	4 4	r	H
4	-	4 9	0	4
3	5	NO	4	3
LO	4	44	N	-
-	-	H H	-	-
T	T	11	T	E

Figure S35. ¹³C-NMR spectrum for **9** in DMSO.

Figure S37. ¹³C-NMR spectrum for **10** in DMSO.

Figure S39. ¹³C-NMR spectrum for **11** in DMSO.

Figure S41. ¹³C-NMR spectrum for **12** in DMSO.

Figure S43. ¹³C-NMR spectrum for **13** in DMSO.

Figure S45. ¹³C-NMR spectrum for **14** in DMSO.

Figure S46. ¹H-NMR spectrum for **15** in DMSO.

Figure S47. ¹³C-NMR spectrum for **15** in DMSO.

62	11	10	2331 2331 2332 2332 2332 2332 2332 2332
-	4	04	44400000404404000
	•		
4	9	00	00400004400000
9	5	2 2	H H M M M M M M M M M M M M M M M M M M
-	-		
		\backslash	

Figure S52. ¹H-NMR spectrum for **18** in DMSO.

Figure S54. ¹H-NMR spectrum for **19** in DMSO.

Figure S57. ¹³C-NMR spectrum for **20** in DMSO.

7. References

- 1. S. Sprouse, K. King, P. Spellane and R. J. Watts, J. Am. Chem. Soc., 1984, 106, 6647-6653.
- 2. L. A. Stott, K. E. Prosser, E. K. Berdichevsky, C. J. Walsby and J. J. Warren, *Chem. Commun.*, 2017, **53**, 651-654.
- 3. M. S. Kabir, M. Lorenz, O. A. Namjoshi and J. M. Cook, Org. Lett., 2010, 12, 464-467.
- 4. R. Schiffmann, A. Neugebauer and C. D. Klein, J. Med. Chem., 2006, 49, 511-522.
- 5. H. Zhang, Q. Cai and D. Ma, J. Org. Chem., 2005, 70, 5164-5173.